摘要
华法林是临床上广泛使用的口服抗凝药物,其治疗范围窄,个体差异大,尤其在治疗初期,易导致严重的出血并发症,如何合理、安全使用成为国内外研究者关注的重点和难点。华法林的疗效受多种因素的影响,以遗传因素中基因多态性较为突出。近年来,随着药物基因组学的快速发展,研究发现药动学和药效学多个相关基因的多态性造成了华法林的个体差异。现从基因多态性角度综述CYP2C9和VKORC1基因的遗传变异对华法林药物反应差异的影响。
Warfarin is widely used as an oral anticoagulant in clinical practice.It has a narrow therapeutic range but a large individual variation.Especially,it leads to serious bleeding complications easily in early treatment.The rational and safe use of warfarin has been becoming a key problem in clinical practice.The efficacy of warfarin is affected by many factors,and the genetic polymorphism of hereditary factors is prominent.In recent years,with the development of pharmacogenomics,the studies show that the genetic polymorphisms of related genes in pharmacokinetics and pharmacodynamics result in interindividual variation in warfarin.We review the effects of genetic polymorphisms,such as CYP2C9 and VKORC1,on drug response and therapeutic efficacy of warfarin.
出处
《医学综述》
2011年第2期178-180,共3页
Medical Recapitulate
